[go: up one dir, main page]

CL2008003821A1 - Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado - Google Patents

Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado

Info

Publication number
CL2008003821A1
CL2008003821A1 CL2008003821A CL2008003821A CL2008003821A1 CL 2008003821 A1 CL2008003821 A1 CL 2008003821A1 CL 2008003821 A CL2008003821 A CL 2008003821A CL 2008003821 A CL2008003821 A CL 2008003821A CL 2008003821 A1 CL2008003821 A1 CL 2008003821A1
Authority
CL
Chile
Prior art keywords
vsv
cell
attenuated
gene
cells
Prior art date
Application number
CL2008003821A
Other languages
English (en)
Inventor
Christopher Parks
Susan Witko
Maninder K Sidhu
J Erik Johnson
Roger Michael Hendry
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2008003821A1 publication Critical patent/CL2008003821A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para producir el virus de la estomatitis vesicular atenuado (VSV) en un cultivo celular; composición inmunogénica que comprende el virus atenuado; célula que comprende un gen g VSV optimizado; secuencia de control transcripcional dela proteína vírica g.
CL2008003821A 2007-12-20 2008-12-19 Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado CL2008003821A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1535307P 2007-12-20 2007-12-20

Publications (1)

Publication Number Publication Date
CL2008003821A1 true CL2008003821A1 (es) 2009-04-03

Family

ID=40418917

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003821A CL2008003821A1 (es) 2007-12-20 2008-12-19 Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado

Country Status (8)

Country Link
US (1) US20090162321A1 (es)
EP (1) EP2225264A1 (es)
JP (1) JP2011507514A (es)
AR (1) AR069885A1 (es)
AU (1) AU2008343919B2 (es)
CA (1) CA2710166A1 (es)
CL (1) CL2008003821A1 (es)
WO (1) WO2009085172A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533345T3 (es) * 2009-06-08 2015-04-09 The University Of Western Ontario Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
CA3075990A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US20200299686A1 (en) * 2017-10-02 2020-09-24 Georgia Tech Research Corporation Methods and Compositions for Engineering Synthetic Bioswitches for Remote Control of Biological Activity
CN109750006A (zh) * 2019-01-14 2019-05-14 青岛农业大学 一种犬瘟热病毒复制缺陷毒株及其构建方法
CN115725657B (zh) * 2022-09-16 2024-06-04 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用
CN117051040B (zh) * 2023-08-15 2024-10-01 北京百普赛斯生物科技股份有限公司 Vsv△g复制缺陷型病毒制备及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
EP1005535B1 (en) * 1997-05-02 2015-11-11 The Uab Research Foundation Attenuation of negative stranded rna viruses by rearrangement of their genes and uses thereof
AU2046801A (en) * 1999-11-23 2001-06-04 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
MXPA05013141A (es) * 2003-06-09 2006-03-17 Wyeth Corp Metodo mejorado para la recuperacion de arn virus de cadena negativa, no segmentados, a partir de adnc.
US8008268B2 (en) * 2006-07-25 2011-08-30 Merial Limited Vaccines against vesicular stomatitis

Also Published As

Publication number Publication date
EP2225264A1 (en) 2010-09-08
AU2008343919B2 (en) 2013-01-17
AR069885A1 (es) 2010-02-24
US20090162321A1 (en) 2009-06-25
AU2008343919A1 (en) 2009-07-09
WO2009085172A1 (en) 2009-07-09
CA2710166A1 (en) 2009-07-09
JP2011507514A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
CL2008003020A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado, que comprende generar celulas que expresan la proteina g de la vsv a partir de un gen vsv optimizado, infectar dichas celulas con el vsv atenuado, y recuperar los virus dle cultivo; composicion que comprende al virus atenuado y kit para producir el virus.
CY1121159T1 (el) Μη-ενσωματουμενοι λεντiϊικοι φορεις
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
PE20120571A1 (es) Produccion de titulos elevados de polivirus para la produccion de vacunas
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
PE20091218A1 (es) Anticuerpo anti-glipicano 3 con cinetica en plasma mejorada
AR039465A1 (es) Sistema multi plasmid para la produccion de virus influenza
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
WO2005042728A3 (en) Immortalized avian cell lines for virus production
MY151119A (en) Duck embryonic derived stem cell lines for the production of viral vaccines
TR201900213T4 (tr) Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu.
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
PE20131401A1 (es) Kit para detectar el virus de la leucemia bovina (blv), y uso del mismo
AR079710A1 (es) Proceso para el cultivo de celulas adherentes
ES2570665T3 (es) Factor de permisividad celular para virus, y usos del mismo
EA201270577A1 (ru) Усовершенствованные способы обратной генетики для спасения вирусов
EA201100902A1 (ru) Новый способ получения рнк-вируса
Liu et al. CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and omicron, and inhibits viral infection
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa
DK1851325T3 (da) Fremgangsmåde til påvisning af levedygtige celler i en prøve ved anvendelse af en virus
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
CL2018002900A1 (es) Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos.
WO2006038129A3 (en) Hepatitis c virus replication system